1. UNAIDS, IN DANGER: UNAIDS Global AIDS Update 2022. Geneva: Joint United Nations Programme on HIV/ AIDS; 2022. Licence: CC BY-NC-SA 3.0 IGO., 2022.
2. United Stated Food and Drug Administration, FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection, (2021). https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection (accessed November 29, 2022).
3. United Stated Food and Drug Administration, FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention, (2021). https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention (accessed November 29, 2022).
4. UNAIDS welcomes the approval of long-acting injectable cabotegravir as a pre-exposure prophylaxis for HIV prevention, (n.d.). https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2021/december/20211222_cabotegravir (accessed December 1, 2022).
5. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744);Johns;J. Med Chem.,2013